Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US40131M1099
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG006D97VY9
GH
Guardant Health Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH
NAME
Guardant Health Inc
ISIN
US40131M1099
TICKER
GH
MIC
XNAS
REUTERS
GH.OQ
BLOOMBERG
GH US
Di., 22.04.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity™ smart liquid biopsy platform at the 2025 American Association for Cancer Resea...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 10.04.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webca...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 03.04.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer Guardant’s portfolio of precision oncology tests across the continuum of cancer care through the Bayshore network of clinic...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 25.03.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA)...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 11.03.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Shield™ blood test for colorectal cancer (CRC) screening. The U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 28.02.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock opti...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 27.02.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” survey, which showed that nine out of ten physicians surveyed are concerned about the percentage of their patients who do not complete colorectal cancer (CRC) screening. In many cases,...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 20.02.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 10.02.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 07.02.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the “2027 Notes”), pursuant to which the Company will issue $600 milli...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 30.01.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 30.01.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational pharmaceuti...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 23.01.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing the benefits of Guardant’s precision oncology tools across cancer screening, recurrence monitoring, treatment selection and therapy development at the American Society of Clinical Oncolog...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 21.01.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following cur...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 16.01.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data (RWD) that integrates comprehensive patient electronic...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 13.01.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 07.01.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ multi-cancer detection (MCD) test for use in its Vanguard study, which will address the feasibility of using MCD tests in future clinical trials related to cancer screening. MCD tests are...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 02.01.2025       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p....
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 20.12.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network....
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 19.12.2024       Guardant Health
US40131M1099

COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care c...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 18.12.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selective...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 09.12.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating the benefits of its precision oncology tests, real-world clinical-genomic database and AI analytics in optimizing therapy selection, identifying resistance mutations, and predicting lo...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 25.11.2024       Guardant Health
US40131M1099

Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera Found to Have Willfully Misled Oncologists in an Effort to Thwart Competition PALO ALTO, Calif., Nov. 25, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nas...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 13.11.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option aw...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 06.11.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excludi...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 01.11.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. ●   Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA     Fireside chat on Tuesday, November 12 at 10:30 a.m. Eastern Time       ●  ...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 30.10.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME’s annual list of the Best Inventions, which features 200 extraordinary innovations changing lives. To compile this year's list, TIME solicited nominations from TIME editors a...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mo., 28.10.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening adherence at the American College of Gastroenterology (ACG) 2024 Annual Meeting in Philade...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 24.10.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. “We a...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 15.10.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the web...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Mi., 18.09.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the peer-reviewed journal Nature Medicine published results from the SCRUM-Japan GOZILA study confirming that selecting targeted therapy on the basis of Guardant360® CDx liquid biopsy results may significantly extend survival for patients with advanced cancer...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 13.09.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Gua...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 10.09.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS (“Policlinico Gemelli”) to establish an in-house liquid biopsy testing service as a part of its diagnostics services within its hospital system. Leveraging Guardant Health’s cuttin...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Di., 27.08.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. Guardant Health’s management is scheduled to participate in a fireside chat on Thursday, September 5th at 11:30 a.m. ET. Interested parties...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 22.08.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will ring the opening bell at the Nasdaq MarketSite in Times Square, New York on Wednesday, August 28, 2024. “We recently launched Shield, our FDA-approved blood-based screening test, marking a pivotal moment on our journey to conquer cancer wit...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 08.08.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Canaccord Genuity 44th Annual Growth Conference in Boston, MA Fireside chat on Tuesday, August 13 at 10:30 a.m. ET UBS Genomic Medicine Summit in Dana Point, CA Panel discussion: Futur...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Do., 23.05.2024       Guardant Health
US40131M1099

Instrument ID [5530668] (5GH - US40131M1099) suspended...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink
Fr., 15.03.2024       Guardant Health
US40131M1099

New York, New York--(Newsfile Corp. - March 15, 2024) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Guardant Health, Inc. (NASDAQ: GH) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and cor...
Zur Nachricht
Guardant Health
Charts & Research Termsheets Terminal
Permalink